The role of new PET tracers for lung cancer

[1]  Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer , 2018, Nature Communications.

[2]  S. Gambhir,et al.  A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management , 2018, Science Translational Medicine.

[3]  C. Craik,et al.  Imaging PD-L1 Expression with ImmunoPET , 2017, Bioconjugate chemistry.

[4]  G. Rubini,et al.  Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives , 2017, International journal of molecular sciences.

[5]  F. Gleeson,et al.  18F‐fluoromisonidazole uptake in advanced stage non‐small cell lung cancer: A voxel‐by‐voxel PET kinetics study , 2017, Medical physics.

[6]  Hong Lu,et al.  A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer , 2017, Scientific Reports.

[7]  Minghui Zhang,et al.  Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma , 2017, Oncotarget.

[8]  A. Windhorst,et al.  Whole body PD-1 and PD-L1 PET with Zr-89-nivolumab and F-18-BMS-986192 in pts with NSCLC. , 2017 .

[9]  G. Cook,et al.  Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Massion,et al.  68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer , 2017, PloS one.

[11]  S. Beck,et al.  Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial , 2017, JAMA oncology.

[12]  L. Eremina,et al.  Cofilin-1 and Other ADF/Cofilin Superfamily Members in Human Malignant Cells , 2016, International journal of molecular sciences.

[13]  G. V. von Schulthess,et al.  TNM Staging of Non–Small Cell Lung Cancer: Comparison of PET/MR and PET/CT , 2016, The Journal of Nuclear Medicine.

[14]  Wei Zhang,et al.  68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer , 2015, The Journal of Nuclear Medicine.

[15]  V. Goh,et al.  Molecular imaging of hypoxia in non-small-cell lung cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  P. Lambin,et al.  A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model. , 2015, International journal of radiation oncology, biology, physics.

[17]  F. Zaccagna,et al.  Non-small-cell lung cancer resectability: diagnostic value of PET/MR , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  P. Heusch,et al.  Thoracic Staging in Lung Cancer: Prospective Comparison of 18F-FDG PET/MR Imaging and 18F-FDG PET/CT , 2014, The Journal of Nuclear Medicine.

[19]  V. Ambrosini,et al.  Molecular imaging of pulmonary nodules. , 2014, AJR. American journal of roentgenology.

[20]  Yong-jie Lu,et al.  Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. , 2014, Cancer Research.

[21]  C. Faivre-Finn,et al.  Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  P. Lambin,et al.  Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  M. Wuest,et al.  Synthesis, characterisation and evaluation of a novel copper-64 complex with selective uptake in EMT-6 cells under hypoxic conditions. , 2013, Dalton transactions.

[24]  Q. Xie,et al.  First Experience of 18F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination , 2013, The Journal of Nuclear Medicine.

[25]  P. Szlosarek,et al.  Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Keigo Endo,et al.  Transport of 3-Fluoro-l-α-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET , 2012, The Journal of Nuclear Medicine.

[27]  D. Lee,et al.  Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. , 2012, Cancer biotherapy & radiopharmaceuticals.

[28]  Paul Kinahan,et al.  Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials , 2012, European Radiology.

[29]  M. Schwaiger,et al.  PET Imaging of Integrin αVβ3 Expression , 2011, Theranostics.

[30]  Luc Thiberville,et al.  Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  J. Barbet,et al.  Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. , 2011, Nuclear medicine review. Central & Eastern Europe.

[32]  Xiaoyuan Chen,et al.  Molecular imaging in cancer treatment , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Ernst J. Rummeny,et al.  Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, αvβ3 Expression, and Glucose Metabolism , 2010, The Journal of Nuclear Medicine.

[34]  O. Boerman,et al.  Molecular imaging of angiogenesis with SPECT , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  A. Alavi,et al.  Non-FDG PET in the practice of oncology. , 2010, Indian journal of cancer.

[36]  Xindong Sun,et al.  Measuring Tumor Cell Proliferation with 18F-FLT PET During Radiotherapy of Esophageal Squamous Cell Carcinoma: A Pilot Clinical Study , 2010, Journal of Nuclear Medicine.

[37]  Zheng Fu,et al.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  V. Prasad,et al.  Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[40]  Bohumil Bednar,et al.  Dual In Vivo Quantification of Integrin-targeted and Protease-activated Agents in Cancer Using Fluorescence Molecular Tomography (FMT) , 2010, Molecular Imaging and Biology.

[41]  V. Ambrosini,et al.  68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  Talakad G. Lohith,et al.  Pathophysiologic Correlation Between 62Cu-ATSM and 18F-FDG in Lung Cancer , 2009, Journal of Nuclear Medicine.

[43]  Y. Fujibayashi,et al.  Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. , 2009, Nuclear medicine and biology.

[44]  J. Overgaard,et al.  The oxygen effect and fractionated radiotherapy , 2009 .

[45]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Jean Tessier,et al.  Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy , 2008, Journal of Nuclear Medicine.

[47]  S. Ben-Haim,et al.  18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response* , 2008, Journal of Nuclear Medicine.

[48]  A. Groves,et al.  A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.

[49]  Xiaoyuan Chen,et al.  PET Imaging of Angiogenesis. , 2009, PET clinics.

[50]  V. Ambrosini,et al.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  Jin-Sook Ryu,et al.  [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung , 2008, Clinical Cancer Research.

[52]  Shyh-Jen Wang,et al.  The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET , 2008, Annals of nuclear medicine.

[53]  V. Ambrosini,et al.  Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  F. Gao,et al.  Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  Jiahe Tian,et al.  A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-18F-Fluorothymidine and 18F-FDG , 2008, Journal of Nuclear Medicine.

[56]  D. Hörsch,et al.  Receptor PET/CT imaging of neuroendocrine tumors. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[57]  A. Scott,et al.  Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.

[58]  W. Oyen,et al.  Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancer , 2007, Cancer.

[59]  Stefano Fanti,et al.  18F-DOPA PET and PET/CT , 2007, Journal of Nuclear Medicine.

[60]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[61]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[62]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[63]  A. Padhani.  PET imaging of tumour hypoxia , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[64]  E. D. de Vries,et al.  Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.

[65]  J. Mortensen,et al.  The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography , 2006, Respiration.

[66]  A. Shields,et al.  Positron Emission Tomography Measurement of Tumor Metabolism and Growth: Its Expanding Role in Oncology , 2006, Molecular Imaging and Biology.

[67]  R. Govindan,et al.  Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  M. Eble,et al.  [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study , 2006, BMC Cancer.

[69]  A. Noël,et al.  Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. , 2005, Cancer biotherapy & radiopharmaceuticals.

[70]  Tadashi Nariai,et al.  Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. , 2005, Journal of neurosurgery.

[71]  Lester J. Peters,et al.  Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[72]  Anne-Marie Sykes,et al.  CT screening for lung cancer: five-year prospective experience. , 2005, Radiology.

[73]  H. Herzog,et al.  PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  U. Haberkorn,et al.  (68)Ga-labeled peptides in tumor imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  Morand Piert,et al.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  T. Mattfeldt,et al.  Clinical relevance of imaging proliferative activity in lung nodules , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  P. Price,et al.  The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  R. Cerfolio,et al.  Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. , 2004, The Annals of thoracic surgery.

[80]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[81]  Georgios Karanikas,et al.  Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  J. Hatazawa,et al.  Tumor detection with carbon-11-labelled amino acids , 1984, European Journal of Nuclear Medicine.

[83]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.

[84]  G. Hutchins,et al.  Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. , 2004, Nuclear medicine and biology.

[85]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Michael J. Welch,et al.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[88]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[89]  Marianne Patt,et al.  [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. , 2003, Nuclear medicine and biology.

[90]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  Hiroshi Fukuda,et al.  Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. , 2003, Nuclear medicine and biology.

[92]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  G. Reifenberger,et al.  Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas , 2002, Child’s Nervous System.

[94]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[95]  Zhihong Zhu,et al.  In Vitro and in Vivo Evaluation of a Technetium-99m-Labeled Cyclic RGD Peptide as a Specific Marker of αVβ3 Integrin for Tumor Imaging , 2002 .

[96]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[97]  Zhihong Zhu,et al.  In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. , 2002, Bioconjugate chemistry.

[98]  V Kalff,et al.  (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[100]  D. Harpole,et al.  Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. , 2001, Lung cancer.

[101]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[102]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[103]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  A. Chiti,et al.  Nuclear medicine imaging of neuroendocrine tumours. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  M. Schwaiger,et al.  Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.

[107]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[108]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[109]  T. Siahaan,et al.  The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[110]  R L Wahl,et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[112]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[113]  R. Galalae,et al.  [Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level]. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[114]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[115]  K Wienhard,et al.  F-Dopa as an amino acid tracer to detect brain tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[116]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[117]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[118]  T. Ido,et al.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[119]  M. Höckel,et al.  Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. , 1993, Gynecologic oncology.

[120]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[121]  J. Rasey,et al.  Reduction of fluoromisonidazole, a new imaging agent for hypoxia. , 1991, Biochemical Pharmacology.

[122]  K. Ishiwata,et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[123]  K. Krohn,et al.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. , 1987, Radiation research.

[124]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[125]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.